Losartan attenuates acetic acid enema-induced visceral hypersensitivity by inhibiting the ACE1/Ang II/AT1 receptor axis in enteric glial cells

Sun, Yating; Liu, Xiaohui; Wang, Lianli; Li, Laifu; Quan, Xiaojing; Shi, Haitao; Wang, Ting; Ma, Lin; Chen, Yindi; Zhang, Yue; Li, Jingyao; Meng, Ruiting; Wang, Jinhai; Dai, Fei

doi:10.1016/j.ejphar.2023.175650

Cited by 1 publication

(1 citation statement)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mechanizm działania losartanu w IBS został częściowo wyjaśniony w badaniu in vitro komórek mikrogleju jelitowego u szczurów z modelem IBS indukowanym kwasem octowym (powodującym obrzęk jelita) oraz lipopolisacharydem. Oprócz zwiększonego stężenia mediatorów stanu zapalnego, w mikrogleju szczurów z IBS odkryto także zwiększoną aktywność osi ACEangiotensyna II -receptor AT1; najpewniej był to punkt działania losartanu 28 . Nie znaleźliśmy żadnego trwającego badania klinicznego mającego określić wpływ losartanu na objawy IBS u ludzi.…”

Section: Losartanunclassified

Recent advances in the treatment of functional dyspepsia and irritable bowel syndrome

Bieniasz,

Bigos,

Dendys

et al. 2023

J Educ Health Sport

View full text Add to dashboard Cite

Introduction and purpose: While irritable bowel syndrome (IBS) and functional dyspepsia (FD) are common problems in everyday clinical practice, their treatment often remains inefficient. The aim of our work is to present the newest discoveries and research conducted in the topic, while putting special accents on methods available in Poland. We decided to refer to British Society of Gastroenterology guidelines of treatment of IBS and FD as commonly accepted treatment standards in Europe. Description of the state of knowledge: Number of patients suffering from IBS and FD remains high. According to current research, there are some new therapeutical options in IBS: fecal microbiota transplant, spinal catepsin S, olorinab and tenapanor. Methods already being in use in other applications such as vitamin D supplementation, losartan and fecal microbiota transplant are also being investigated. Fecal microbiota transplant seems the most promising one. There are no new treatment options in FD, however there are new research on already used rifaximin and prokinetics, which show their efficacy. Intensive research is being conducted on the use of herbal medicines in treatment of FD. Even though some papers prove the effectiveness of acupuncture we have decided to omit this topic due to its controversial nature. Conclusions: Treatment of IBS and FD remains difficult, there are few advances in that area. Unconventional methods such as herbal medicine and fecal microbiota transplant seem to be gaining in importance.

show abstract

Section: Losartanunclassified